Endothelin receptor antagonists inhibit antigen-induced lung inflammation in mice.
In this study, we have examined the effect of endothelin (ET) receptor antagonists on lung granulocyte inflammation after antigen challenge in sensitized mice. The antagonists used were BQ-123, an ETA antagonist, BQ-788, an ETB antagonist, and SB209670, an ET(A&B) antagonist. Thirty minutes prior exposure to aerosolized ovalbumin, ET antagonists (50 pmol/mouse) were administered directly into the lungs of sensitized Balb/c mice via the intranasal route. BQ-123 and SB209670 significantly decreased eosinophil number in the bronchoalveolar lavage fluid by 47 and 68%, respectively. Both compounds also inhibited neutrophil infiltration into the lungs. In contrast, BQ-788 did not affect granulocyte infiltration. A similar inhibition of lung eosinophilia was also obtained with an anti-ET antibody applied via the intranasal route. BQ-123 and SB209670, but not BQ-788, significantly increased the production of interferon-gamma (Th1 cytokine) from purified lung Thy1.2+ cells without affecting interleukin-4 and interleukin-5 (Th2 cytokines) secretion. Furthermore, neutralizing antibody against interferon-gamma prevented the inhibitory effect of the ETA antagonist. Taken together, these results suggest an important pathophysiologic role for ET in the development of lung inflammation in asthma and highlight the potential of ET antagonists for the treatment of the disease.
Fujitani
Y
Y
Department of Respiratory Diseases and Allergy, Ciba-Geigy Ltd., Basel, Switzerland.
Trifilieff
A
A
Tsuyuki
S
S
Coyle
A J
AJ
Bertrand
C
C
D000281:Administration, Intranasal; D000336:Aerosols; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000941:Antigens / Q000276:immunology*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002465:Cell Movement / Q000187:drug effects; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000276:immunology; D006098:Granulocytes / Q000502:physiology; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D015848:Interleukin-5 / Q000096:biosynthesis; D008168:Lung / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009842:Oligopeptides / Q000494:pharmacology*; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D010456:Peptides, Cyclic / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D011014:Pneumonia / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control*
D000336:Aerosols; D000911:Antibodies, Monoclonal; D000941:Antigens; D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D015848:Interleukin-5; D009842:Oligopeptides; D010456:Peptides, Cyclic; D010880:Piperidines; D015847:Interleukin-4; C086539:BQ 788; D007371:Interferon-gamma; D010047:Ovalbumin; C072247:cyclo(Trp-Asp-Pro-Val-Leu)